Graham Collins: TRANSFORM Study – Liso-Cel vs Standard 2nd Line in 1st Relapse Large B-Cell NHL
Graham Collins, Associate Professor, Haematology and Lymphoma Specialist at Oxford Cancer and Haematology Centre, shared a post on X:
“Kamdar et al; 3y FU of TRANSFORM study – Liso-cel vs standard 2nd line in 1st relapse large B-cell NHL.
Impressive PFS & EFS benefit Trend to OS but not stat significant. 66% crossed over to liso-cel from control arm.
No new tox signal.”
Title: Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study
Authors: Manali Kamdar, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Victor A. Chow, Sandrine Montheard, Josu Santamaria, Silvia Colicino, Ken Ogasawara, Lara Stepan, Fei Fei Liu, Jeremy S. Abramson
More posts featuring Graham Collins on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023